Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ibitors and protease inhibitors that are in late-stage

preclinical testing.

"In 2007, Idenix experienced a great deal of change, which enabled us to reassess the strategic direction of our company and reevaluate our focus," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "I am very pleased to report that the company continues to be grounded by a strong scientific foundation that enables us to rapidly discover novel antiviral drug candidates. As we begin 2008, we are a stronger, leaner organization that will devote all of our resources to the discovery and continued development of antiviral drugs for the treatment of HCV and HIV."

Financial Results

For the fourth quarter ended December 31, 2007, Idenix reported total revenues of $12.6 million, compared with total revenues of $15.3 million in the fourth quarter of 2006. Total revenues for the fourth quarter of 2007 consisted primarily of reimbursement by Novartis of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R), the amortization of up front fees associated with development programs licensed by Novartis, and royalties associated with worldwide sales of Tyzeka/Sebivo. The $2.7 million reduction in total revenues for the fourth quarter of 2007 as compared to the fourth quarter of 2006 is due primarily to lower development expenses associated with licensed programs and subsequent reimbursement of such expenses by Novartis.

Idenix reported a net loss of $17.5 million, or a loss of $0.31 per basic and diluted share for the fourth quarter ended December 31, 2007, compared to a net loss of $23.6 million, or a loss of $0.42 per basic and diluted share for the fourth quarter ended December 31, 2006. The $6.1 million reduction in net loss for the fourth quarter of 2007 as compared to the fourth quarter of 2006 is due primarily to lower selling, general and administrative expenses incurred as a result of a restructuring
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
2. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Notice of Bradmer Pharmaceuticals Conference Call
6. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
8. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
9. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
10. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
11. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 Today marks ... all-new online Itinerary Builder. , The redesigned and ... create unique vacation itineraries on their computer or mobile ... , The interactive tool allows users to fill in ... browse through and select their choice of vacation packages, ...
(Date:5/24/2013)... American Fork, Utah (PRWEB) May 24, 2013 ... several years now and is excited to announce it’s new weight ... our product that we are offering our customers their money back ... says Dave Sherwin, CEO of HCG EZ Drops. “The HCG ... caloric intake; hence the 21 pounds in 21 days.” , The ...
(Date:5/23/2013)... Magnatag’s new magnetic 365-Day attendance and vacation monitor ... A Manufacturing Manager from Augusta GA told us, “We ... managers can check the board for themselves and we ... us and the board makes the record public so ... it has made a difference.” , “Our customers ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 Internationally ... coaching educators in tennis for over 29 years, ... than 50 ATP & WTA players, Grand Slam winners, ... Italian Open Champions, 25 USTA National Junior Champions, 8 ... Junior Champions, including Sunshine Cup, Orange Bowl and Eddie ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2
... CLARA, Calif., FURSTENFELDBRUCK, Germany and YOKOHAMA CITY,Japan, ... real-time,compression technology company, Schleifring und Apparatebau GmbH, ... medical and defense markets,and Tokyo Electron Device ... boards, today announced an agreement for the ...
... the May/June issue of Health Affairs reports on the ... what one might expect from chronic disease management programs ... news for state Medicaid leaders struggling to meet the ... that some disease management efforts, even among relatively low-risk ...
... ... Quality Act (CEQA)., LOS ANGELES, May 12 ... planned expansion of its,Holy Cross Medical Center even as Superior Court ... was significantly flawed.,The groundbreaking ceremony held today appears to be an ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
... Board:,NTRZ), a world leader in stabilized rice bran (SRB), ... first quarter ended,March 31, 2008. Consolidated net revenues rose ... compared to consolidated net revenues of $2.0,million for the ... due to a $860,000 increase in sales of products ...
... Baptist Health South,Florida Inc., a health care system ... $7,775,000 to settle claims that it violated the,False Claims ... by paying,excessive compensation to an oncology group that was ... the Department of Justice,announced today. The payments were made ...
Cached Medicine News:Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 2Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 3Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 4Health News:Chronic disease management: Does it improve health and save money? 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6Health News:Florida Hospital Group Pays U.S. $7,775,000 to Settle False Claims Act Allegations 2
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today announced ... other conditions, shares of its common stock in an underwritten public ... the offering may be completed, or as to the actual size ... is acting as sole book-running manager for the offering.  ...
... Gore & Associates is among just five workplaces to ... to Work For" since the rankings debuted three decades ... its workforce, earned the No. 38 spot on the ... (Photo:  http://photos.prnewswire.com/prnh/20120119/PH38553 ) Headquartered in Newark, Del., ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2W. L. Gore & Associates Named a Top U.S. Workplace 2
... Triad Skull Clamp, compatible with the full ... of clamping force on all three skull ... the possibility of adjusting the force on ... be increased or decreased by adjusting the ...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
... PocketChem UA is the first ... take up valuable lab bench space. ... the variability in results between operators ... on every run, corrects for ambient ...
... sensor catheters incorporate a lumen ... wire, or high-speed injection/guide wire. ... injection has two laterally opposed ... open-end pigtail extension for use ...
Medicine Products: